UNSPSC 51203405: Mercaptopurine ribonucleoside

This classification denotes a purine antagonist and immunosuppressant with the molecular formula C10H12N4O4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 46S541971T, chemically known as 9h-purine-6(1h)-thione, 9-.beta.-d-ribofuranosyl-, but more generally known as mercaptopurine ribonucleoside, which bears US NIH Compound Identifier 676166. European Medicines Agency schedules mercaptopurine ribonucleoside or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12149MIG.

Most nations, for tariff purposes, schedule mercaptopurine ribonucleoside under HS 29335995. SMILES: C1NC2C(C(N1)S)NCN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O.

UNSPSC 51203405 Mercaptopurine ribonucleoside is a Commodity code that shows minimal relevant recent activity under state and local procurement. The code nominally denotes a specific antimetabolite pharmaceutical compound, yet the recent opportunities posted under this code—including Seminole County's procurement of naloxone and drug deactivation systems, the City of Tampa's medical and first aid supplies bid, the Texas HHS Commission's therapeutic pharmacy initiative RFI, and the Minnesota Multistate Cooperative Purchasing Alliance's generic pharmaceuticals and OTC products RFP—do not align with mercaptopurine ribonucleoside procurement. The mismatch suggests either a taxonomy coding error in the state and local systems or that the code captures a broader pharmaceutical supply category than its name indicates. None of the recent solicitations explicitly target mercaptopurine ribonucleoside or similar single-compound oncology pharmaceuticals.

Without sourced evidence of active state and local solicitations specifically for mercaptopurine ribonucleoside, no reliable characterization of issuing-body mix, geographic concentration, or representative current opportunities can be drawn from the available records. The code shows no documented recent contract activity matching its nominal scope across the state and local market during the review period.